EPO published patent application EP3710049A1, filed by University of Washington inventors Edward A. Clark, Che-Leung Law, Deborah Fuller, and Michael Gale, covering a therapeutic HBV vaccine using PreS1/PreS2 and/or S-HBsAg regions of the HBV envelope protein. The application is classified under IPC codes A61K 39/12, A61K 39/29, A61K 39/00, and C07K 16/28, with designated states covering all major European jurisdictions including DE, FR, GB, IT, ES, NL, and 25 other EPO member states.

Pharmaceutical and biotechnology companies engaged in HBV vaccine development should review freedom-to-operate implications and consider patent landscape analysis for their existing or planned HBV therapeutic programs. Research institutions and vaccine developers should assess whether this patent coverage affects their development activities in the designated territories.